Hsbc Holdings PLC Makes New Investment in Radiopharm Theranostics Limited – Sponsored ADR $RADX

Hsbc Holdings PLC bought a new position in Radiopharm Theranostics Limited – Sponsored ADR (NASDAQ:RADX) during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund bought 191,624 shares of the company’s stock, valued at approximately $1,007,000.

Other institutional investors also recently modified their holdings of the company. Marex Group plc bought a new stake in Radiopharm Theranostics during the fourth quarter worth $54,000. Jane Street Group LLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at $76,000. Finally, Virtu Financial LLC bought a new position in Radiopharm Theranostics in the 4th quarter valued at $76,000.

Wall Street Analysts Forecast Growth

RADX has been the subject of several research analyst reports. HC Wainwright assumed coverage on Radiopharm Theranostics in a research report on Thursday, June 4th. They set a “buy” rating and a $6.00 target price for the company. Weiss Ratings restated a “sell (e+)” rating on shares of Radiopharm Theranostics in a research report on Tuesday, April 21st. Two equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Radiopharm Theranostics currently has a consensus rating of “Hold” and a consensus target price of $11.00.

Radiopharm Theranostics Stock Performance

Shares of RADX opened at $4.33 on Tuesday. Radiopharm Theranostics Limited – Sponsored ADR has a 1 year low of $3.62 and a 1 year high of $16.25. The stock’s fifty day moving average price is $4.40 and its two-hundred day moving average price is $4.68.

Radiopharm Theranostics Company Profile

Radiopharm Theranostics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of radiopharmaceutical products for both diagnostic imaging and targeted radiotherapeutic applications. By harnessing the unique properties of radioisotopes, the company aims to improve the precision of disease detection and deliver therapeutic payloads directly to diseased tissues, particularly in oncology.

The company’s research and development efforts are concentrated on a pipeline of radioligand therapies and companion diagnostic agents designed to address a variety of tumor types.